For patients with advanced or metastatic EGFR‐mutant NSCLC, immunotherapy alone has limited benefit [8]; thus, second‐ or later‐line salvage treatments for patients with multiple lesions are usually composed of combination regimens. This evidence concerns the gene EGFR and non-small cell lung carcinoma.